MTOR and cancer: Thus, targeting P62 may be effective in some cancers, as demonstrated by the inhibition of P62 in bladder cancer that increases the sensitivity to the anti-cancer drug NVP-BEZ235, which also functions as an inhibitor PI3K/mTOR [158].